CSL Announces Full Year Results

CSL Continues Strong International Growth

Melbourne, Australia — 22/08/2001

CSL announced today that it has achieved another year of strong growth in profit and revenue. Group sales rose by 87% to $843.3m producing a profit after tax, before amortisation of goodwill, of $102.4m, an increase of 88% on the previous year's result. Net profit after tax was $78.2m, an increase of 44% over the previous year. A significant highlight of this result is that 61% of CSL Group sales was derived from international sales.

This result is largely consistent with the announcement of an earnings upgrade made by the Company on 26 June, 2001.

The Directors have declared a final dividend of 17c per share fully franked payable on 11 October, 2001, bringing the total dividend for the year to 26c per share.

CSL's Managing Director, Dr Brian McNamee, said, "One of the key drivers of this performance has been the successful integration and performance of ZLB Bioplasma AG and the launch of its products into the US. This result confirms the benefits of our strategy of becoming a global plasma products business, highlighted by the recent acquisition of Nabi's plasma collection business, completion of which is expected shortly.

"It is anticipated that with the acquisition of this plasma collection business, ZLB Bioplasma will be in a position to rely on long-term supplies of US sourced plasma which will continue to drive volumes and earnings for the Bioplasma group.

"It is also pleasing to note that we have been able to increase our expenditure on R&D across the Group to a total of $81m, an increase of 86% over R&D expenditure last year."

Dr McNamee said that profit growth remained strong in CSL's other businesses with good performances by the JRH Biosciences Group achieving 23% growth in revenue and by Biocor Animal Health, Inc which performed strongly through increasing sales in the US market of its own animal vaccine range. 

Analyst Presentation (PDF, 0.19MB) - 22 August 2001


For further information contact:

Dr Brian McNamee
Managing Director
Ph: +61 3 9389 1375

Mr Tony Cipa
Finance Director
Ph: +61 3 9389 1319
© 2016 CSL Limited